Compare Corning Incorporated (GLW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Corning (GLW) trades at $157.74, down 4.8% in the last session amid broader market volatility. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and projected 2026 revenue growth to $17B. Technical indicators are mixed with a neutral overall signal while valuation metrics remain elevated with a P/E of 73.36. Recent analyst upgrades highlight AI infrastructure and optical communications growth potential.

GLW presents a compelling growth story driven by AI data center demand and optical communications expansion, though premium valuation requires flawless execution. Key risks include competitive pressures in photonics and sensitivity to technology spending cycles. With 57% analyst buy ratings and a $193.33 consensus target offering 23% upside, the stock warrants consideration for growth-oriented investors despite near-term volatility.

Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.

Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.